title: [Bacterial phagelysates and malignant tumor growth].
abstract: Anti-tumor preventive efficacy of E.coli phagelysate has been studied. Investigations were conducted on 2-3 months 48 male mice. Regimen of preventive vaccinations were: single - 0,25 ml phagelysate intraperitoneal injection, 3 days before Ehrlich carcinoma inoculation (1x10(6) tumor cells); 3 times vaccinations (0,25 ml, with 3 day intervals) 3, 6, and 9 days before inoculation of carcinoma; and 10 times (during 10 days, before inoculation of carcinoma). Treatment efficacy was evaluated according to the indices of cancer growth (development of cancer tissue, cancer growth inhibition percent, lifespan and survival percent). Experiments have shown that single and 3 times preventive vaccinations inhibited tumor development and delayed malignant growth, while, 10 times permanent vaccinations had no effects on cancer growth. Cancer growth inhibition percent in single and 3 times vaccinated animals were 58% on the average. Maximal lifespan in control group mice consisted 59 days. By the 125th day of cancer growth, at single vaccination 17% of mice were alive, while in 3 times vaccinated mice the survival percent was 25%. Anti-tumor potential of E.coli pagelysate supposedly could be explained by immunoregulatory properties of the preparation.
authors.affiliation: Tbilisi State Medical University, Georgia.
authors.forename: K
authors.initials: K
authors.lastname: Gambashidze
authors.affiliation: Tbilisi State Medical University, Georgia.
authors.forename: N
authors.initials: N
authors.lastname: Bejitashvili
authors.affiliation: Tbilisi State Medical University, Georgia.
authors.forename: T
authors.initials: T
authors.lastname: Azaladze
authors.affiliation: Tbilisi State Medical University, Georgia.
authors.forename: M
authors.initials: M
authors.lastname: Pkhaladze
authors.affiliation: Tbilisi State Medical University, Georgia.
authors.forename: A
authors.initials: A
authors.lastname: Azaladze
mesh_terms: D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D004926:Escherichia coli; D007167:Immunotherapy / Q000379:methods*; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D016896:Treatment Outcome